Immix Biopharma, Inc.
- IMMX
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech
- Oncology/Inflammation Therapeutics
$8.13
Today +1.88%Quote Oct 19, 2026, 04:09 PM UTC
−37.26%over the last month
Max drawdown −37.8%From 1-month high −37.8%3 months −9.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Immix Biopharma
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
21
Founded
2012
Market value
$581.6M
Quote Oct 19
Floor
$7.47
8.2% below price
Resistance
$8.22
1.1% above price
Price vs analyst targets
6 analysts
Lowest target
$19.00Highest target
$26.00
$19.00Highest target
$26.00
- Price $8.13
- Average target $23.33
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 187% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IMMXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free